- Home
- IFRX vs RENB Comparison
IFRX vs RENB Comparison
Compare IFRX & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- RENB
- Stock Information
- Founded
- IFRX 2007
- RENB 2011
- Country
- IFRX Germany
- RENB United States
- Employees
- IFRX N/A
- RENB N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- IFRX Health Care
- RENB Health Care
- Exchange
- IFRX Nasdaq
- RENB Nasdaq
- Market Cap
- IFRX 65.8M
- RENB 61.0M
- IPO Year
- IFRX 2017
- RENB N/A
- Fundamental
- Price
- IFRX $1.69
- RENB $0.32
- Analyst Decision
- IFRX Strong Buy
- RENB
- Analyst Count
- IFRX 4
- RENB 0
- Target Price
- IFRX $8.50
- RENB N/A
- AVG Volume (30 Days)
- IFRX 262.5K
- RENB 1.4M
- Earning Date
- IFRX 05-07-2025
- RENB 05-27-2025
- Dividend Yield
- IFRX N/A
- RENB N/A
- EPS Growth
- IFRX N/A
- RENB N/A
- EPS
- IFRX N/A
- RENB N/A
- Revenue
- IFRX $140,242.00
- RENB N/A
- Revenue This Year
- IFRX $61.96
- RENB N/A
- Revenue Next Year
- IFRX $80.59
- RENB N/A
- P/E Ratio
- IFRX N/A
- RENB N/A
- Revenue Growth
- IFRX 30.90
- RENB N/A
- 52 Week Low
- IFRX $0.82
- RENB $0.29
- 52 Week High
- IFRX $2.82
- RENB $2.34
- Technical
- Relative Strength Index (RSI)
- IFRX 62.40
- RENB 39.35
- Support Level
- IFRX $1.53
- RENB $0.30
- Resistance Level
- IFRX $1.92
- RENB $0.55
- Average True Range (ATR)
- IFRX 0.19
- RENB 0.06
- MACD
- IFRX 0.02
- RENB 0.01
- Stochastic Oscillator
- IFRX 74.59
- RENB 13.96
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.